MCCs in adults with autoimmune and inflammatory rheumatic diseases: evidence to date and future directions
Therapeutic Advances in Musculoskeletal Disease · 2026-07 · 18
DOI: 10.1177/1759720x261462685 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Musculoskeletal Disease, online erschienen am 25.07.2026. Verfasst von Namrata Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Multiple chronic conditions (MCCs), also known as multimorbidity, are highly prevalent in adults with autoimmune and inflammatory rheumatic diseases (AIIRDs) and significantly complicate their management. This narrative review summarizes current literature on the epidemiology of MCCs in various AIIRDs, highlighting their association with adverse health outcomes and proposing future directions for care. MCCs are ubiquitous across AIIRDs, often exceeding rates seen in age-matched general populations, with prevalence as high as 86% in rheumatoid arthritis and 81.5% in systemic lupus erythematosus cohorts and notable patterns including cardiopulmonary and mental health disorders frequently observed. This substantial MCC burden is consistently linked to adverse outcomes, including increased all-cause mortality, reduced functional status, diminished health-related quality of life, accelerated disability, higher healthcare utilization, and increased costs, driven by chronic inflammation, lifestyle, and treatment effects. Therefore, rheumatology care must adopt a holistic, person-centered framework that actively recognizes and manages MCCs, leveraging multidisciplinary teams and integrating evidence-based interventions guided by frameworks such as the geriatric 5Ms and 5Ts to advance the science of MCCs in adults with AIIRDs and improve outcomes and optimize health-related quality of life in this complex patient population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA.
- Division of Geriatric Medicine, Division of Health Systems Science, UMass Chan Medical School, Worcester, MA, USA.
- Division of Rheumatology, Department of Medicine, Hospital for Special Surgery, New York, NY, USA.
- Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
ORCID-Profile: Namrata Singh
Förderung
- NIA NIH HHS
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institute on Aging
Zitieren
APA
Singh, N., Gurwitz, J. H., & Lieber, S. B. (2026). MCCs in adults with autoimmune and inflammatory rheumatic diseases: evidence to date and future directions. Therapeutic Advances in Musculoskeletal Disease, 18. https://doi.org/10.1177/1759720x261462685
Vancouver
Singh N, Gurwitz JH, Lieber SB. MCCs in adults with autoimmune and inflammatory rheumatic diseases: evidence to date and future directions. Therapeutic Advances in Musculoskeletal Disease. 2026;18. doi:10.1177/1759720x261462685
BibTeX
@article{Singh2026,
author = {Singh, Namrata and Gurwitz, Jerry H and Lieber, Sarah B},
title = {MCCs in adults with autoimmune and inflammatory rheumatic diseases: evidence to date and future directions},
journal = {Therapeutic Advances in Musculoskeletal Disease},
year = {2026},
volume = {18},
doi = {10.1177/1759720x261462685}
}
EUVIMED